Loading…
Bacil Pharma (BSE 524516)₹16.82−1.29%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Bacil Pharma reported sales of ₹0 Cr and net profit of −₹0.08 Cr. For the year to Mar 2026, sales were ₹0 Cr and net profit ₹1.57 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Jun 2026 | Sep 2026 | |
|---|---|---|
| Sales | 0.00 | 0.00 |
| Expenses | 0.01 | 0.05 |
| Operating Profit | −0.01 | −0.05 |
| Other Income | 0.08 | 0.08 |
| Interest | 0.00 | 0.07 |
| Depreciation | 0.00 | 0.00 |
| Profit before tax | 0.06 | −0.02 |
| Tax % | 114.4% | 133.4% |
| Net Profit | −0.03 | −0.08 |
| EPS (Rs) | 0.00 | −0.04 |
| Mar 2026 | |
|---|---|
| Sales | 0.00 |
| Expenses | 0.24 |
| Operating Profit | −0.24 |
| Other Income | 1.23 |
| Interest | 0.00 |
| Depreciation | 0.00 |
| Profit before tax | 0.98 |
| Tax % | −57.5% |
| Net Profit | 1.57 |
| EPS (Rs) | 1.08 |
| Dividend payout % | 0.0% |
| Mar 2026 | |
|---|---|
| Cash from operating activity | 1.70 |
| Cash from investing activity | −3.39 |
| Cash from financing activity | −0.61 |
| Net cash flow | −2.30 |
| Free cash flow | 1.70 |
| CFO / OP % | −684.0% |
For the Sep 2026 quarter, Bacil Pharma reported sales of ₹0 Cr and net profit of −₹0.08 Cr.
Bacil Pharma's sales for the year to Mar 2026 were ₹0 Cr.
Net profit for the year to Mar 2026 was ₹1.57 Cr. Earnings per share over the same trailing period were ₹1.08.
Cash from operations was ₹1.70 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹1.70 Cr.